Efficacy and Safety of Once-Daily Tadalafil in Men with Erectile Dysfunction Who Reported No Successful Intercourse Attempts at Baseline

Authors

  • Ridwan Shabsigh MD,

    Corresponding author
    1. Division of Urology, Maimonides Medical Center, New York, NY, USA
      Ridwan Shabsigh, MD, Division of Urology, Maimonides Medical Center, 904 49th Street, New York, NY 11219, USA. Tel: 718-283-7746; Fax: 718-283-7424; E-mail: rshabsigh@gmail.com
    Search for more papers by this author
  • Allen D. Seftel MD,

    1. Division of Urology, Urology Residency Training Program, Cooper Medical School of Rowan University, Camden, NJ, USA
    Search for more papers by this author
  • Edward D. Kim MD,

    1. Division of Urology, Department of Surgery, University of Tennessee Graduate School of Medicine, Knoxville, TN, USA
    Search for more papers by this author
  • Xiao Ni PhD,

    1. Lilly Research Laboratories, Eli Lilly and Company (Lilly USA, LLC), Indianapolis, IN, USA
    Search for more papers by this author
  • Patrick R. Burns PharmD

    1. Lilly Research Laboratories, Eli Lilly and Company (Lilly USA, LLC), Indianapolis, IN, USA
    Search for more papers by this author

  • Funding statement. The four base studies and the reported analysis were sponsored by Eli Lilly and Company (Lilly USA, LLC; Indianapolis, IN, USA).

  • Previous presentation. Selected findings were presented at the Sexual Medicine Society of North America 2011 Annual Fall Meeting, Las Vegas, NV, USA, November 10–13, 2011 (Moderated Poster 129).

  • ClinicalTrials.gov registration. Internal study identifiers H6D-MC-LVFZ (Clinicaltrials.gov identifier NCT00547183); H6D-MC-LVFP (NCT00381732); H6D-MC-LVGH (NCT00422734); and H6D-MC-LVCV (non–US trial; no NCT #).

Ridwan Shabsigh, MD, Division of Urology, Maimonides Medical Center, 904 49th Street, New York, NY 11219, USA. Tel: 718-283-7746; Fax: 718-283-7424; E-mail: rshabsigh@gmail.com

ABSTRACT

Introduction.  Tadalafil is efficacious and well tolerated for erectile dysfunction (ED), but effects in men with “complete ED” are unclear.

Aim.  To investigate effects of once-daily tadalafil in men with no successful intercourse attempts at baseline.

Methods.  Through a post hoc, pooled-data analysis of four randomized, double-blind trials on the effects of tadalafil 2.5 or 5 mg (vs. placebo) in men with ED, we evaluated efficacy and safety in subjects with 0 “yes” responses to Sexual Encounter Profile question 3 (SEP3) during an initial 4-week treatment-free run-in period.

Main Outcome Measures.  Changes from baseline in the SEP diary and the International Index of Erectile Function-erectile function (IIEF-EF) domain were subjected to analysis of covariance models.

Results.  Five hundred ninety-five subjects with no successful attempts at baseline were included in the analysis. The mean (±standard deviation) age was 58.2 ± 10.7 years; and most subjects had ED for ≥1 year (95.0%). ED was severe in 61.5% and moderate in 26.4%. Approximately 45% had diabetes mellitus or hypertension. After 12 weeks, the mean per-patient SEP3 percentage increased from 0% to 32.4% with tadalafil 2.5 mg and to 46.4% with tadalafil 5 mg (each P < 0.001 vs. placebo). Corresponding data for successful penetration (SEP2) were increases from 21.1% to 48.2% with tadalafil 2.5 mg and from 24.4% to 66.2% with 5 mg (each P < 0.001 vs. placebo). Mean IIEF-EF increased from 9.7 to 15.7 with tadalafil 2.5 mg and from 10.7 to 19.2 with 5 mg (each P < 0.001 vs. placebo). Tadalafil also significantly improved the intercourse-satisfaction and overall-satisfaction domains (vs. placebo). Both doses of tadalafil were generally well tolerated, with adverse event rates similar to placebo.

Conclusions.  The posttreatment intercourse success rate was 32% and 46% for tadalafil 2.5 mg and 5 mg, respectively, in men with no successful intercourse attempts at baseline. Shabsigh R, Seftel AD, Kim ED, Ni X, and Burns PR. Efficacy and safety of once-daily tadalafil in men with erectile dysfunction who reported no successful intercourse attempts at baseline. J Sex Med 2013;10:844–856.

Ancillary